Pfizer Inc. announced detailed overall survival data from the PALOMA-3 trial, which evaluated Ibrance (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease progressed on or after prior endocrine therapy.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
